Format

Send to

Choose Destination
Shock. 2011 Jan;35(1):42-4. doi: 10.1097/SHK.0b013e3181e83204.

Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection.

Author information

1
Infectious Disease Research Laboratory, Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA. Steven_Opal@brown.edu

Abstract

Human inter-α inhibitor proteins are endogenous human plasma proteins that function as serine protease inhibitors. Inter-α inhibitor proteins can block the systemic release of proteases in sepsis and block furin-mediated assembly of protective antigen, an essential stop in the intracellular delivery of the anthrax exotoxins, lethal toxin and edema toxin. Inter-α inhibitor proteins administered on hour or up to 24 h after spore challenge with Bacillus anthracis Sterne strain protected mice from lethality if administered with antimicrobial therapy (P < 0.001). These human plasma proteins possess combined actions against anthrax as general inhibitors of excess serine proteases in sepsis and specific inhibitors of anthrax toxin assembly. Inter-α inhibitor proteins could represent a novel adjuvant therapy for the treatment of established anthrax infection.

PMID:
20523269
PMCID:
PMC3016999
DOI:
10.1097/SHK.0b013e3181e83204
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center